MDXG News and Press, MiMedx Group Inc From 04/28/21

MiMedx Group (MDXG): Q1 GAAP EPS of -$0.09 beats by $0.10.Revenue of $59.7M (-3.2% Y/Y) misses by $0.2M.Press Release For further details see: MiMedx Group EPS beats by $0.10, misses on revenue

First Quarter Net Sales of $60.0 Million Advancing Innovative Late-Stage Musculoskeletal Pipeline with Data Readouts Expected in Q3 2021 Company to Host Conference Call on April 29, 2021 at 8:30 AM ET MARIETTA, Ga., April 28, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, ...

Accomplished Regulatory Leader Joins MiMedx Management Team MARIETTA, Ga., April 28, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative m...

Gainers: Reviva Pharmaceuticals RVPH +41%, Ocugen OCGN +22%, Axsome Therapeutics AXSM +12%, AcelRx Pharmaceuticals (ACRX) +9%, Voyager Therapeutics VYGR +8%.Losers: MiMedx (MDXG) -9%, Shineco (TYHT) -8%, Brooklyn ImmunoTherapeut...

MARIETTA, Ga., April 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report financial results for the...

MiMedx (MDXG) announces that the last patients have completed their clinical visits in two late-stage trials of AmnioFix Injectable as a potential treatment for Plantar Fasciitis and Achilles Tendonitis.In addition, all clinical effectiveness endpoint visits have been completed in a Phase 2B ...

Advances Potential for Use of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) as a Safe and Effective Treatment Option On Track to Advance Planned Analyses and Announce Top-Line Data in Plantar Fasciitis, Achilles Tendonitis and Knee Osteoarthritis in Q3 2021 ...

No Shareholder Action Required at This Time MARIETTA, Ga., April 16, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today confir...

Prescience Point Capital Management to Nominate Four Highly Qualified Director Candidates to MiMedx Board at 2021 Annual Meeting Sends Letter to Fellow MiMedx Shareholders Citing Board's Failure to Maximize Shareholder Value PR Newswire BATON ROUGE, La. , A...

Some major changes in my portfolio in March including an entrance back into a few China stocks, some new Healthcare picks, and a new large financial SPAC position. I also sold off some of my more defensive value positions during the last rotation to add to some of my key tech position...